专利检索 ap:("Novartis AG") AND inv:"Tom Thuren" 第 1 页

1.

发明申请
USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE 审中-公开

公开(公告)号：US20200148759A1

公开(公告)日：2020-05-14

申请号：US16448341

申请日：2019-06-21

申请人： Novartis AG

发明人： Craig Basson , Tom Thuren , Shi Yin Foo , Mark C. Fishman

IPC分类号： C07K16/24

摘要： The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1β binding antibody or functional fragment thereof.

2.

发明申请
USE OF IL-1beta BINDING ANTIBODIES 审中-公开

公开(公告)号：US20190048072A1

公开(公告)日：2019-02-14

申请号：US15970542

申请日：2018-05-03

申请人： Novartis AG

发明人： Monica Ligueros-Saylan , Patrice Matchaba , Tom Thuren , Paul Ridker , Peter Libby , Penelope OTTEWELL , Yi Yang LAU , Margaret DUGAN

IPC分类号： C07K16/24 , A61P35/00 , G01N33/574 , A61K9/00

摘要： Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis.

3.

发明申请
USE OF IL-1 BETA BINDING ANTIBODIES FOR TREATING PERIPHERAL ARTERIAL DISEASE 审中-公开

公开(公告)号：US20180258166A1

公开(公告)日：2018-09-13

申请号：US15984993

申请日：2018-05-21

申请人： Novartis AG

发明人： Craig Basson , Tom Thuren , Shi Yin Foo , Mark C. Fishman

IPC分类号： C07K16/24

CPC分类号： C07K16/245 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92

摘要： The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1β binding antibody or functional fragment thereof.

4.

发明授权
Methods of reducing the risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered a qualifying CV event 有权

公开(公告)号：US10975145B2

公开(公告)日：2021-04-13

申请号：US15483619

申请日：2017-04-10

申请人： Novartis AG

发明人： Tom Thuren , Andrew Zalewski , Michael Shetzline

IPC分类号： C07K16/24 , A61K39/00

摘要： The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.

5.

发明申请
Use of IL-1ß Binding Antibodies 审中-公开

公开(公告)号：US20170275358A1

公开(公告)日：2017-09-28

申请号：US15483619

申请日：2017-04-10

申请人： Novartis AG

发明人： Tom Thuren , Andrew Zalewski , Michael Shetzline

IPC分类号： C07K16/24 , A61K39/00

CPC分类号： C07K16/245 , A61K2039/505 , A61K2039/545 , C07K2317/21

摘要： The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.